Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01910610
Recruitment Status : Recruiting
First Posted : July 29, 2013
Last Update Posted : June 16, 2021
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
GERCOR - Multidisciplinary Oncology Cooperative Group

Tracking Information
First Submitted Date  ICMJE July 23, 2013
First Posted Date  ICMJE July 29, 2013
Last Update Posted Date June 16, 2021
Actual Study Start Date  ICMJE October 30, 2013
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 11, 2021)
Duration of Disease Control (DDC) [ Time Frame: From baseline until end of strategy; up to 80 months after the beginning of the study ]
DDC is defined as the sum of PFS of each active treatment course planned in the treatment strategy. DDC excludes 1) intervals between disease progression and re-initiation of treatment, and 2) PFS of inactive treatment if PD occurs at first evaluation after treatment re-initiation (either reintroduction in a stop-and-go strategy or subsequent course of treatment in a multi-line strategy).
Original Primary Outcome Measures  ICMJE
 (submitted: July 25, 2013)
Duration of Disease Control [ Time Frame: From baseline until end of strategy, assessed up to 80 months after the beginning of the study ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 11, 2021)
  • Assessment of Quality of life (QoL) [ Time Frame: From baseline until end of strategy; up to 80 months after the beginning of the study ]
    QoL will be considered to be improved if at least one time to QoL score deterioration (5 targeted dimensions) will be significantly longer without a significant shorter time to QoL score dimensions for other 4 targeted dimensions.
  • Overall Survival (OS) [ Time Frame: Up to 80 months after the beginning of the study ]
    Time from randomization to the date of death from any cause
  • Time to Failure of Strategy (TFS) [ Time Frame: Up to 80 months after the beginning of the study ]
    TFS is defined as beginning with the initiation of the strategy under investigation and ending with the first of the following events: 1) death, 2) disease progression on the last received planned sequence, 3) patient requires the addition of a new (unplanned) therapeutic agent, 4) patient experiences disease progression during a partial or complete break in therapy from initial treatment strategy and receives no further therapy within one month.
  • Progression-free survival (PFS) per sequence of therapy [ Time Frame: Up to 80 months after the beginning of the study ]
    Time from randomization to the date of first documented disease progression or death from any cause, whichever occurs first.
  • Tumor Response Rate (RR) [ Time Frame: From baseline until end of strategy; up to 80 months after the beginning of the study ]
    Tumor response will be assessed using RECIST version 1.1 per sequence of therapy
  • Curative salvage surgery rate [ Time Frame: From baseline until end of strategy; up to 80 months after the beginning of the study ]
    The number of patient with R0 and R1 curative salvage surgery will be assessed globally (per arm) and per sequence of therapy
  • Safety profile of each treatment sequence [ Time Frame: From study entry to 1 month after last study drug administration; up to 80 months after the beginning of the study ]
    The report will take into account all adverse events observed during and after drug administration, including any adverse events that may be related to the administration procedure itself.
Original Secondary Outcome Measures  ICMJE
 (submitted: July 25, 2013)
  • Quality of life [ Time Frame: from baseline until end of strategy, assessed up to 80 months after the beginning of the study ]
    QoL will be considered to be improved if at least one time to QoL score deterioration (Five targeted dimensions) will be significantly longer without a significant shorter time to QoL score dimensions for other 4 targeted dimensions.
  • Overall Survival [ Time Frame: time interval from randomization to the date of death from any cause. Assessed up to 80 months after the beginning of the study. ]
  • Time to Failure of Strategy [ Time Frame: Assessed up to 80 months after the beginning of the study ]
    TFS is defined as beginning with the initiation of the strategy under investigation and ending with the first of the following events: 1) death, 2) disease progression on the last received planned sequence, 3) patient requires the addition of a new (unplanned) therapeutic agent, 4) patient experiences disease progression during a partial or complete break in therapy from initial treatment strategy and receives no further therapy within one month.
  • Progression-free survival (PFS) per sequence of therapy [ Time Frame: the time interval from randomization to the date of first documented disease progression or death from any cause, whichever occurs first. Assessed up to 80 months after the beginning of the study ]
  • Tumor Response Rate (RR) [ Time Frame: from baseline until end of strategy, assessed up to 80 months after the beginning of the study ]
  • Curative salvage surgery rate [ Time Frame: from baseline until end of strategy, assessed up to 80 months after the beginning of the study ]
  • Safety profile of each treatment sequence [ Time Frame: Assessed from study entry to 1 month after last study drug administration, assessed up to 80 months after the beginning of the study ]
    The study will take into account all adverse events observed during and after drug administration, with a particular interest for: Any AE Any serious AE Any serious AE related to study treatment Any NCI-CTC grade 3 or 4 AE Any AE causing discontinuation of study treatment Any AE causing a dose reduction of study medication Any AE leading to death
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer
Official Title  ICMJE Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.
Brief Summary STRATEGIC-1 is a study designed to determine the best sequence of therapy in patients with metastatic colorectal cancer.
Detailed Description

This is a phase III study assessing 2 mutli-line therapeutic strategies in patients with unresectable wild-type RAS metastatic colorectal cancer. All the available treatments are being used in each strategy (oxaliplatine, irinotecan, fluoropyrimidines, bevacizumab, cetuximab or panitumumab) but in a different order:

STRATEGY A: FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab vs.

STRATEGY B: OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Colorectal Cancer Metastatic
Intervention  ICMJE
  • Biological: FOLFIRI-cetuximab
  • Biological: mFOLFOX6-bevacizumab
  • Biological: OPTIMOX-bevacizumab
  • Biological: irinotecan-based chemo + bevacizumab
  • Biological: Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)
  • Biological: XELOX + bevacizumab
Study Arms  ICMJE
  • Experimental: STRATEGY A
    FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab
    Interventions:
    • Biological: FOLFIRI-cetuximab
    • Biological: mFOLFOX6-bevacizumab
    • Biological: XELOX + bevacizumab
  • Experimental: STRATEGY B
    OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan
    Interventions:
    • Biological: OPTIMOX-bevacizumab
    • Biological: irinotecan-based chemo + bevacizumab
    • Biological: Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)
    • Biological: XELOX + bevacizumab
Publications * Chibaudel B, Bonnetain F, Tournigand C, de Larauze MH, de Gramont A, Laurent-Puig P, Paget J, Hadengue A, Notelet D, Benetkiewicz M, André T, de Gramont A. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC Cancer. 2015 Jul 4;15:496. doi: 10.1186/s12885-015-1503-7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 25, 2013)
474
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2021
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Signed and dated informed consent, and willing and able to comply with protocol requirements,
  2. Histologically proven adenocarcinoma of the colon and/or rectum,
  3. Wild-type RAS tumor no mutation in exon 2 [codon 12/13], exon 3 [codon 59/61] and exon 4 [codon 117/146] of both KRAS and NRAS genes (local assessment, performed either on primary tumor or metastasis), In exceptional circumstances, RAS mutational status (KRAS and NRAS) can be pending at time of randomization, provided it is obtained within the first two cycles of first line therapy
  4. Metastatic disease confirmed,
  5. No prior therapy for metastatic disease (in case of previous adjuvant therapy, interval from end of chemotherapy and relapse must be >6 months for fluoropyrimidine alone or >12 months for oxaliplatin-based, bevacizumab-based, or cetuximab-based therapy),
  6. Duly documented unresectable metastatic disease, ie not suitable for complete carcinological surgical resection at inclusion [NB: patients with unresectable disease at study entry but with any potential of salvage surgery after induction therapy are eligible],
  7. At least one measurable or evaluable lesion as assessed by CT-scan or MRI (Magnetic Resonance Imaging) according to RECIST v1.1,
  8. Age ≥18 years,
  9. ECOG Performance status (PS) 0-2,
  10. Hematological status: neutrophils (ANC) ≥1.5x109/L; platelets ≥100x109/L; haemoglobin ≥9g/dL,
  11. Adequate renal function: serum creatinine level <150µM,
  12. Adequate liver function: serum bilirubin ≤1.5 x upper normal limit (ULN), alkaline phosphatase <5xULN,
  13. Proteinuria <2+ (dipstick urinalysis) or ≤1g/24hour,
  14. Baseline evaluations performed before randomization when the KRAS WT status is known: clinical and blood evaluations no more than 2 weeks (14 days) prior to randomization, tumor assessment (CT-scan or MRI, evaluation of non-measurable lesions) no more than 3 weeks (21 days) prior to randomization,
  15. Female patients must commit to using reliable and appropriate methods of contraception during the trial and until at least six months after the end of study treatment (when applicable). Male patients with a partner of childbearing potential must agree to use contraception in addition to having their partner use another contraceptive method during the trial and until at least 6 months after the end of the study treatment,
  16. Registration in a national health care system (CMU included for France).

Exclusion Criteria:

  1. History or evidence upon physical examination of CNS metastasis (e.g. non irradiated CNS metastasis, seizure not controlled with standard medical therapy), unless adequately treated,
  2. Exclusive bone metastasis,
  3. Uncontrolled hypercalcemia,
  4. Pre-existing permanent neuropathy (NCI grade ≥2),
  5. Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy,
  6. Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy),
  7. Treatment with any investigational medicinal product within 28 days prior to study entry,
  8. Other serious and uncontrolled non-malignant disease,
  9. Gilbert's syndrome,
  10. Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years,
  11. Major surgery (open biopsy, surgical resection, wound revision or any other major surgery involving entry into body cavity) or significant traumatic injury within the last 28 days prior to randomization, and/or minor surgical procedure including placement of a vascular device within 2 days of first study treatment,
  12. Pregnant or breastfeeding women,
  13. Patients with known allergy/hypersensitivity to any component of study drugs,
  14. History of arterial thrombo and/or embolic event (e.g. myocardial infarction, stroke,…) within 6 months prior to randomization,
  15. Chronic inflammatory bowel disease
  16. Total bowel obstruction,
  17. History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to randomization,
  18. Serious, non-healing wound, active ulcer or untreated bone fracture,
  19. History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding,
  20. Current or recent (within 10 days of randomization) use of aspirin (>325 mg/d), clopidogrel (>75 mg/d) or use of oral anticoagulants or thrombolytic agents.
  21. Concomitant administration of live, attenuated virus vaccine such as yellow fever vaccine
  22. Concomitant administration of prophylactic phenytoin.
  23. Treatment with sorivudine or its chemically related analogues, such as brivudine.
  24. Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.
  25. Concomitant use with St John's Wort
  26. Patients with interstitial pneumonitis or pulmonary fibrosis
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Benoist Chibaudel, MD +33(0)1 47 59 19 23
Listed Location Countries  ICMJE France,   Ireland,   Israel
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01910610
Other Study ID Numbers  ICMJE STRATEGIC-1 C12- 2
2013-001928-19 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party GERCOR - Multidisciplinary Oncology Cooperative Group
Original Responsible Party Same as current
Current Study Sponsor  ICMJE GERCOR - Multidisciplinary Oncology Cooperative Group
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Hoffmann-La Roche
Investigators  ICMJE
Principal Investigator: Benoist Chibaudel, MD Institut Hospitalier Franco-Britannique
PRS Account GERCOR - Multidisciplinary Oncology Cooperative Group
Verification Date June 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP